Thomas Holm Pedersen – CEO – NMD Pharma | LinkedIn
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma - Inkef capital
NMD Pharma brænder 41 mio. kr. af sin kæmpeinvestering
NMD Pharma
Management — NMD Pharma
NMD Pharma - Inkef capital
NMD Pharma A/S | LinkedIn
NMD Pharma
NMD Pharma - PIR International
Biotech completes financing round to advance neuromuscular treatments - EPM Magazine
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders
News — NMD Pharma
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
Foundations invest DKK 280 million in biomedical company
NMD Pharma - PIR International
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
Management — NMD Pharma
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
Oct 23 | Neuromuscular Drug Development Summit (NMD) | Boston, MA Patch
Dutch MG Clinical Trial Will Test NMD670 Oral Therapy Candidate
NMD Pharma treats first patient with the firm's most promising drug candidate
Rare Neuromuscular Disease Company NMD Pharma Raises USD 3 Million in Seed Financing Round - Lundbeckfonden
ALS Therapy Developer NMD Pharma Obtains $47 Million in New Financing
NMD Pharma treats first patient with the firm's most promising drug candidate
